Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

IDDO and MORU released its Medicine Quality Scientific Literature Surveyor. The surveyor delivers summaries of published scientific reports on the quality of the classes of essential medicines listed below, across regions and over time. We hope it will help medicine regulators, scientists, health professionals, purchasers and officials fill critical information gaps.

Africa and Asia map

Substandard and falsified (SF) medical products (medicines, vaccines, diagnostic tests and devices) pose an immediate danger to many people worldwide, and in the case of anti-infectives, they could also increase the threat of drug resistance emerging and spreading. A major challenge in preventing this is a lack of accessible and reliable information on how widespread they really are. This new mapping tool visualises these data and it will help scientists, health professionals and officials fill critical information gaps. 

Funded by Wellcome, the tool delivers summaries of published scientific reports on the quality of communicable diseases (antimalarials, antiretrovirals, antibiotics, anti-tuberculosis) non-communicable diseases (antidiabetics and medical devices for diabetes management, cardiovascular medicines and medical devices), veterinary medicines, and vaccines across regions and over time, both in English and French.

It builds on the success of the Medicine Quality team’s work on WWARN’s existing Antimalarial Surveyor and future phased releases are planned that will expand its reach to other medical products.  

With increasing number of reports in the scientific literature of substandard and falsified medical products for diagnosis, treatment and prevention of COVID-19 we are developing a Surveyor database and map for these, including past reports of SF medicines being repurposed for COVID-19.

Read more on the IDDO website

Similar stories

RECOVERY Trial announced as overall winner of Best COVID-19 Response Project Award in the UK

The RECOVERY Trial has won the Project Management Institute’s Special Covid-19 UK Response Project Award. The award specifically recognised RECOVERY’s work to investigate whether the cheap steroid dexamethasone was an effective treatment for patients hospitalised with severe COVID-19.

ISARIC COVID-19 clinical database passes ½ million patient records mark

COVID-19 has exposed our vulnerability to pandemic infections and shown what works, and what does not. It has tested the effectiveness of the Oxford-based global, open-source, collaborative approach set up 10 years ago to prevent illness and deaths from infectious disease outbreaks: ISARIC, the International Severe Acute Respiratory and Emerging Infection Consortium.

RECOVERY Trial named joint winner of HDR UK’s Impact of the Year Award

The RECOVERY trial has been jointly awarded Health Data Research UK’s 2021 Impact of the Year Award. This award is open to projects which had effectively used health data to improve people’s lives, including through clinical practice, policy, software, algorithms, or publications. The award was presented by James O’Shaughnessy at HDR UK’s online Annual Scientific Conference: Data Insights in a Pandemic.

Latest data on immune response to COVID-19 reinforces need for vaccination, says Oxford-led study

A new study led by the University of Oxford has found that previous infection, whether symptomatic or asymptomatic, does not necessarily protect you long-term from COVID-19, particularly against new Variants of Concern.

RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that the investigational antibody combination developed by Regeneron reduces the risk of death when given to patients hospitalised with severe COVID-19 who have not mounted a natural antibody response of their own.

Professors Peter Horby and Guy Thwaites recognised in Queen’s Birthday Honours

The pioneering work of members of the University of Oxford has been recognised in The Queen's Birthday Honours List. The honorands include Professor Peter Horby and six researchers that have played key roles in leading the University’s response to the Coronavirus pandemic, from the development of new vaccines to the discovery of new drug treatments. Professor Guy Thwaites is appointed a Member of the Order of the British Empire.